Az XM nem nyújt szolgáltatásokat az Amerikai Egyesült Államok lakosai számára.
R
R

Regeneron


Hírek

Regeneron loses key defense in 19 treatment patent lawsuit

Regeneron loses key defense in COVID-19 treatment patent lawsuit By Blake Brittain Oct 4 - Biotech company Regeneron Pharmaceuticals REGN.O lost a bid on Friday to be held immune from allegations that it misused a patented protein while testing a COVID-19 treatment. U.S. District Judge Philip Halpern rejected Regeneron's pretrial argument that he should throw out Allele Biotechnology and Pharmaceuticals' patent lawsuit over the treatment based on a federal law allowing the use of patented invent
P
R

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Constellation Energy Corp CEG.OQ +3.9% Diamondback Energy Inc FANG.OQ +3.7% NVIDIA Corp NVDA.OQ +3.0% Paccar Inc PCAR.OQ +2.8% Trade Desk Inc TTD.OQ +2.2% Bottom Performers Percent Change Tesla Inc TSLA.OQ -3.9% Warner Bros Discovery Inc WBD.OQ -3.5% Take-Two Interactive Software Inc TTWO.OQ -2.9% Moderna Inc MRNA.OQ -2.8% Regeneron Pharmaceuticals Inc REGN.OQ -2.8% The Nasdaq 100
N
P
R
T
T
U
D
T

U.S. stocks weekly: Streaking in September

RPT-BUZZ-U.S. stocks weekly: Streaking in September Repeats from Friday with no changes to text. Updates chart ** S&P 500 .SPX extends winning streak to three weeks, adds 0.6% amid tame inflation data and China stimulus boost .N ** SPX on pace for monthly gain, take that September! ** Dow .DJI and Nasdaq .IXIC also up three consecutive weeks, though the latter still lined up at the velvet rope ** This as benchmark Treasury yield perks up , but can't hold 3-week highs after PCE ** Most sectors fl
A
C
M
R
V
L
W
U
U

U.S. stocks weekly: Streaking in September

BUZZ-U.S. stocks weekly: Streaking in September ** S&P 500 .SPX extends winning streak to three weeks, adds 0.6% amid tame inflation data and China stimulus boost .N ** SPX on pace for monthly gain, take that September! ** Dow .DJI and Nasdaq .IXIC also up three consecutive weeks, though the latter still lined up at the velvet rope ** This as benchmark Treasury yield perks up , but can't hold 3-week highs after PCE ** Most sectors fleet of foot: Materials sprint to front of the pack, while Energ
A
C
M
R
V
L
W
U
U

U.S. STOCKS IonQ, Cassava Sciences, MeridianLink

BUZZ-U.S. STOCKS ON THE MOVE-IonQ, Cassava Sciences, MeridianLink Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The blue-chip Dow rose on Friday to hit an intraday record and small-cap stocks outperformed after a benign inflation report cleared the way for the Federal Reserve to focus on shoring up the labor market while continuing its interest rate easing.
C
E
R
S
R
W
U
U
G
C
L

U.S. STOCKS Regeneron, HP Inc, Honeywell International

BUZZ-U.S. STOCKS ON THE MOVE-Regeneron, HP Inc, Honeywell International Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The blue-chip Dow rose on Friday to hit an intraday record high and small-cap stocks outperformed after a benign inflation report cleared the way for the Federal Reserve to focus on shoring up the labor market while continuing its interest rate easing.
A
C
E
L
R
S
W
W
U
U
D
C
L

Regeneron rises as US FDA approves Dupixent for 'smoker's lung'

BUZZ-Regeneron rises as US FDA approves Dupixent for 'smoker's lung' ** Shares of Regeneron Pharmaceuticals REGN.O rise 1.6% to $1,056.92 in early trading ** Co and French partner Sanofi SASY.PA say the U.S. FDA has approved their blockbuster drug, Dupixent, for patients with a chronic lung disease commonly known as "smoker's lung" ** Dupixent is t
R
S

Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'

UPDATE 2-Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung' Adds details on Dupixent in paragraphs 2 and 4, analyst estimates in paragraph 5, trial details in paragraph 8 By Sriparna Roy Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi SASY.PA and Regeneron's REGN.O blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the companies said on Friday.
R
S

Dupixent approved in United States as first-ever biologic medicine for patients with COPD

BRIEF-Dupixent approved in United States as first-ever biologic medicine for patients with COPD Sept 27 (Reuters) - Sanofi SA SASY.PA /REGENERON REGN.O : PRESS RELEASE: DUPIXENT APPROVED IN THE US AS THE FIRST-EVER BIOLOGIC MEDICINE FOR PATIENTS WITH COPD PRESS RELEASE: DUPIXENT APPROVED IN THE US AS THE FIRST-EVER BIOLOGIC MEDICINE FOR PATIENTS WI
R
S

US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'

US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung' Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi SASY.PA and Regeneron's REGN.O blockbuster drug Dupixent for patients with a chronic lung disease commonly known as "smoker's lung", the companies said on Friday. Reporting by Sriparna Roy in Bengaluru; Editi
R
S

What to Watch in the Day Ahead - Friday, September 27

What to Watch in the Day Ahead - Friday, September 27 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT Federal Reserve Board Governor Michelle Bowman is set to participate in a conversation before the Alabama Bankers Association Bank CEO Meeting in Birmingham, Alabama.
B
R
S

Amgen falls after reporting mixed data on two drugs

BUZZ-Amgen falls after reporting mixed data on two drugs ** Shares of Amgen AMGN.O fall as much as 4.4% to a near two-month low of $316.22 ** Stock is set for its worst day in nearly two months if losses hold ** Late on Tuesday drugmaker said its drugs Uplizna and rocatinlimab, for a rare muscular disorder and a skin disease, respectively, met the
A
R
S

Amgen's muscular disorder drug meets main goal in late-stage study

UPDATE 4-Amgen's muscular disorder drug meets main goal in late-stage study Amgen's Uplizna succeeds in study for muscle-weakening Analysts say data from another experimental drug not 'competitive' Shares fall 2% in extended trading on mixed datasets Adds analyst comments in paragraphs 4, 10 and 11, trial data in paragraph 3, 8 and 9, exec comment in paragraph 6 By Bhanvi Satija and Puyaan Singh Sept 24 (Reuters) - Amgen AMGN.O said on Tuesday that its drug helped improve daily activities includ
A
A
R
S

Regeneron falls after Leerink Partners downgrades to 'market perform', cuts PT

BUZZ-Regeneron falls after Leerink Partners downgrades to 'market perform', cuts PT Updates * * Shares of drugmaker Regeneron REGN.O fall 4.09% to $1,047.29 ** Brokerage Leerink Partners downgrades co to "market perform" from "outperform," cuts PT to $1,077 from $1,175 ** Says trigger for the downgrade was a court ruling for co's 2 milligram dose version of eye-care drug Eylea ** On Monday, a federal judge in West Virginia said REGN cannot immediately block U.S.
A
R

Amgen gets early win in Regeneron lawsuit over Eylea biosimilar

UPDATE 1-Amgen gets early win in Regeneron lawsuit over Eylea biosimilar Adds reponse from Regeneron to Sept 23 story in paragraph 4, corrects company locations in paragraphs 8 and 9 By Blake Brittain Sept 23 (Reuters) - Regeneron REGN.O cannot immediately block U.S. sales of rival Amgen's AMGN.O proposed copy of its blockbuster eye-care drug Eylea, a federal judge in West Virginia said on Monday.
A
R

Amgen gets early win in Regeneron lawsuit over Eylea biosimilar

UPDATE 1-Amgen gets early win in Regeneron lawsuit over Eylea biosimilar Adds reponse from Regeneron to Sept 23 story in paragraph 4, corrects company locations in paragraphs 8 and 9 By Blake Brittain Sept 23 (Reuters) - Regeneron REGN.O cannot immediately block U.S. sales of rival Amgen's AMGN.O proposed copy of its blockbuster eye-care drug Eylea, a federal judge in West Virginia said on Monday.
A
R

U.S. STOCKS Copper miners, Biogen, Salesforce

BUZZ-U.S. STOCKS ON THE MOVE-Copper miners, Biogen, Salesforce Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were set for a subdued open on Tuesday, as investors scoured for clues on what the Federal Reserve's next policy move might be, while commodity stocks got a boost after China unveiled a bumper stimulus package.
A
B
C
M
N
R
S
S
V
L
R
W
U

U.S. Costco Wholesale, McKesson, Starbucks

CORRECTED-U.S. RESEARCH ROUNDUP-Costco Wholesale, McKesson, Starbucks Corrects named item code to RCH/US from RCH/EUROPE, the same error was there in a previous version of the U.S. research roundup Sept 24 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Costco Wholesale, McKesson and Starbucks, on Tuesday.
C
R
S
M
C
L

U.S. STOCKS Copper miners, Biogen, Salesforce

BUZZ-U.S. STOCKS ON THE MOVE-Copper miners, Biogen, Salesforce Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures were muted in choppy trading on Tuesday, as investors scoured for clues on what the Federal Reserve's next policy move might be, while mining stocks got a boost after China unveiled a bumper stimulus package.
A
B
C
N
R
S
V
R
U

Leerink Partners downgrades Regeneron to 'market perform', cuts PT

BUZZ-Leerink Partners downgrades Regeneron to 'market perform', cuts PT ** Brokerage Leerink Partners downgrades Regeneron REGN.O to "market perform" from "outperform," cuts PT to $1,077 from $1,175 ** Says trigger for the downgrade was a court ruling for co's 2 milligram dose version of eye-care drug Eylea ** On Monday, a federal judge in West Virginia said REGN cannot immediately block U.S.
A
R



Feltételek

Népszerű eszközök

Felelősségkizáró nyilatkozat: Az XM Group entitásai csak végrehajtási szolgáltatást és online kereskedési platformunkhoz való hozzáférést biztosítanak, ami lehetővé teszi, hogy a felhasználók megtekinthessék és/vagy felhasználhassák a honlapon vagy azon keresztül elérhető tartalmakat, amelyek nem módosíthatók és nem egészíthetők ki. A hozzáférés és felhasználás mindig a következők függvénye: (i) Felhasználási feltételek; (ii) Kockázati figyelmeztetés; valamint (iii) Teljes felelősségkizáró nyilatkozat. Az ilyen tartalmakat ezért csupán általános információként biztosítjuk. Külön felhívjuk figyelmét arra, hogy az online kereskedési platformunkon található tartalmak nem felhívások vagy ajánlatok tranzakciókba történő belépésre a pénzügyi piacokon. A pénzügyi piacokon folytatott kereskedés jelentős kockázattal jár a tőkéjére nézve.

Az online kereskedési platformunkon közzétett anyagok kizárólag oktatási / tájékoztatási célt szolgálnak, és nem tartalmaznak (nem tekinthető úgy, hogy tartalmaznak) pénzügyi, befektetési adóügyi vagy kereskedési tanácsokat vagy ajánlásokat, illetve kereskedési áraink jegyzékét, vagy bármilyen pénzügyi instrumentummal végrehajtott tranzakcióra vonatkozó ajánlatot vagy felhívást, vagy Önnek szóló kéretlen pénzügyi promóciókat.

Az ezen a honlapon szereplő, külső felektől származó, valamint az XM által készített tartalmak, például vélemények, hírek, kutatások, elemzések, árak és egyéb információk vagy külső felek oldalaira utaló hivatkozások „jelenlegi állapotukban”, általános piaci magyarázatként jelennek meg, és nem minősülnek befektetési tanácsnak. Amennyiben bármely tartalom befektetéssel kapcsolatos kutatásként értelmezhető, meg kell értenie és el kell fogadnia, hogy a tartalom nem a befektetéssel kapcsolatos kutatás függetlenségének előmozdítására szolgáló jogi követelmények szerint készült, következésképpen a vonatkozó törvények és jogszabályok szerint marketingkommunikációnak minősül. Kérjük, feltétlenül olvassa el és értse meg a fenti információkkal kapcsolatos „nem független befektetéskutatással kalcsolatos tájékoztatónkat” és a kockázati figyelmeztetésünket, amelyek itt érhetők el.

Kockázati figyelmeztetés: A CFD összetett eszköz, és a tőkeáttétel miatt a hirtelen veszteség jelentős kockázatával jár. Ennél a szolgáltatónál a lakossági befektetői számlák 73.91%-án veszteség keletkezik a CFD-kereskedés során. Fontolja meg, hogy érti-e a CFD-k működését és hogy megengedheti-e magának a veszteség magas kockázatát. Kérjük, olvassa el a kockázati figyelmeztetés erre vonatkozó részleteit.